peptide purity FAQ

The CoA is falsified—legitimate suppliers print batch numbers on both vials and corresponding documentation using the same tracking system to ensure traceability. Mismatched batch numbers mean the supplier either fabricated the CoA using a template from a different batch or purchased generic documentation from a third party. This is a hard disqualification: without batch-specific verification, you have no evidence the peptide was tested at all. Contact the supplier to request corrected documentation—if they cannot provide a CoA with matching batch number within 48 hours, request a full refund and source from a verified supplier. In the peptide research field, batch number mismatches are the single clearest indicator of counterfeit or grey-market sourcing.

Assume partial degradation has occurred and request replacement with proper cold-chain shipping. Lyophilised peptides undergo thermal degradation at temperatures above 25°C—the degradation rate doubles with each 10°C increase in temperature. A peptide exposed to 35°C summer shipping temperatures for 48 hours loses approximately 20–30% potency compared to properly stored product. The degradation is irreversible: re-freezing the peptide after warm exposure does not restore lost activity. Visual inspection cannot detect this degradation because the peptide still appears as white powder and may reconstitute normally. The only reliable indicator is biological activity testing, which most researchers cannot perform in-house. Reputable suppliers like Real Peptides use insulated packaging with gel packs or dry ice for all shipments during months when ambient temperatures exceed 20°C.

Discard the vial immediately and contact the supplier for replacement—persistent cloudiness indicates either peptide aggregation from improper lyophilisation or presence of non-peptide contaminants. Authentic oxytocin dissolves completely in bacteriostatic water within 60 seconds under gentle swirling. Cloudiness that does not clear suggests the peptide has denatured during storage or synthesis, forming insoluble aggregates that cannot cross cell membranes or bind receptors. Using cloudy peptide solutions introduces both efficacy risk (zero biological activity) and safety risk (potential immunogenic response to aggregated proteins). Real Peptides replaces any vial showing abnormal reconstitution behavior without requiring return shipping.

Switch suppliers immediately. Refusal to provide raw analytical data is the single strongest indicator of low-quality or counterfeit peptides. Authentic research-grade suppliers provide HPLC chromatograms, MS spectra, and endotoxin test results as standard documentation for every batch. Transparency is a quality signal. Suppliers who offer only summary certificates, scanned images of certificates without batch numbers, or claim proprietary restrictions on analytical data are concealing purity or sequencing failures. At Real Peptides, raw HPLC files and MS data are available for every compound including Semax, Selank, and Pe-22-28 upon request. Because verifiable quality is the foundation of reproducible research.

Do not use the solution. Visible particulates indicate peptide aggregation, incomplete dissolution due to incorrect pH, or contamination with insoluble synthesis byproducts. Aggregated peptides have altered biological activity and can clog microinjection needles or filtration systems in experimental setups. Verify that you used bacteriostatic water (not saline or buffer) for reconstitution, as incorrect solvent pH can cause precipitation. If particulates appear despite correct reconstitution, the peptide batch is likely degraded or impure. Request HPLC and MS verification from the supplier before proceeding.

Discard the vial and request a replacement from the supplier with full analytical documentation. Clumping indicates moisture retention from improper lyophilisation or storage, and discolouration (yellow, brown, or grey tint) signals oxidation of amino acid residues. Both are irreversible degradation indicators. Attempting to reconstitute degraded powder produces inconsistent peptide concentrations and may introduce oxidised byproducts that confound experimental results, particularly in studies involving oxidative stress pathways or mitochondrial function.

A mass discrepancy larger than ±1 Da means the peptide sequence is incorrect or the peptide has undergone post-synthesis modification. Common causes include incomplete deprotection (residual protecting groups add 100–200 Da), oxidation of methionine or cysteine residues (adds +16 Da per oxidation), or synthesis errors where the wrong amino acid was incorporated. Do not use the peptide. The biological activity will differ from the intended sequence, and any experimental results will be invalid. Request a new batch with verified mass spec data before proceeding.

If the peptide will be used in cell culture, animal studies, or any biological assay, absence of endotoxin testing is a hard stop. Bacterial endotoxin contamination is invisible. It doesn't affect HPLC purity, molecular weight, or appearance, but it causes immune activation in cells and animals that confounds experimental results. Request LAL assay data from the supplier with results below 1.0 EU/mg for cell culture or below 0.1 EU/mg for in vivo use. If the supplier cannot provide this, source the peptide from a certified provider like Real Peptides where endotoxin testing is standard protocol.

Multiple large peaks indicate the sample contains significant impurities or degradation products. The target peptide is not the dominant species. Contact the supplier immediately for a replacement or request detailed peak identification via mass spec to determine if secondary peaks are deletion sequences, oxidation products, or unrelated compounds. A research-grade peptide should show one dominant peak representing ≥95% of total peptide content, with impurity peaks below 2–3% each. Multiple peaks above 5% signal incomplete purification or improper storage that caused degradation post-synthesis.

Contact the supplier immediately and request a replacement or refund—batch-to-batch variation should not drop below the advertised specification by more than 0.5%. Verify the COA lists batch number, synthesis date, and analytical method (RP-HPLC with gradient details). Legitimate suppliers like Real Peptides provide batch-specific documentation with HPLC chromatograms showing the target peak and impurity profile. If the purity drop is consistent across multiple batches, the supplier's synthesis or purification process has degraded—source from a provider with documented quality control like our full peptide collection where every batch ships with third-party verification.

Perform a secondary purification step in-house using preparative HPLC with a different column chemistry than the vendor used for initial purification. If the vendor used reverse-phase C18, switch to a C4 column with a shallower acetonitrile gradient. This often resolves deletion peptides that co-elute on C18. Collect the main peak fraction, lyophilize, and re-analyze by HPLC to confirm purity improvement. This approach typically increases purity by 2–3 percentage points but requires access to HPLC equipment and extends peptide preparation time by 3–5 days. For peptides where 98%+ purity is non-negotiable. Such as Sermorelin used in growth hormone receptor binding studies. The investment in secondary purification eliminates the dominant source of experimental error.

The deletion peptides in the remaining 5% are likely competing for receptor binding without full activation, shifting your EC50 and preventing saturation. Switch to a 98% pure batch of the same peptide and re-run the assay—if the curve now plateaus cleanly, impurity interference was the variable. This is common with peptides like Ipamorelin or Hexarelin where truncated sequences missing the C-terminal residues bind growth hormone secretagogue receptors but fail to activate the Gq signaling cascade. You're not seeing bad technique—you're seeing pharmacological interference from synthesis by-products.

Not necessarily—HPLC chromatograms always show multiple peaks because no synthesis is 100% pure. The target peptide appears as the dominant peak, with smaller peaks representing deletion sequences, salts, and residual solvents. Purity percentage is the area under the target peak divided by total peak area. Examine the chromatogram: if the target peak accounts for 98% of the total area and the remaining peaks are small (each <1%), the peptide meets research-grade standards. If you see a second large peak representing 5–10% of the total area, that's a deletion peptide—the batch doesn't meet spec and should be rejected. Real Peptides provides annotated chromatograms that label the target peak and identify major impurities so you're not interpreting raw HPLC output.

Request the raw HPLC chromatogram and verify the integration method used to calculate purity. Vendors sometimes use manual baseline correction or peak integration settings that overestimate the target peptide peak area by 2–5%. If the chromatogram shows poorly resolved peaks or a rising baseline, the reported purity may reflect operator judgment rather than objective measurement. Re-analyze the peptide using an independent HPLC method with a shallower gradient to improve peak separation. If additional impurity peaks emerge, the true purity is lower than stated. For dose-response studies already underway, calculate a correction factor based on the true purity and adjust all stock concentrations retroactively to maintain internal consistency across your dataset.

Multiple MS peaks usually indicate oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, or residual TFA adducts that don't significantly alter retention time on HPLC. Check the mass difference between peaks: a +16 Da shift from the expected mass indicates methionine oxidation, while a +1 Da shift suggests deamidation. Both modifications occur during storage if the peptide is exposed to air or stored in solution rather than lyophilized. If MS shows peaks at +96 Da or +196 Da intervals, the peptide contains TFA adducts from incomplete removal during lyophilization. These don't affect biological activity but skew concentration measurements if you're quantifying by weight rather than UV absorbance. For oxidation-sensitive peptides, store under argon or nitrogen atmosphere at −20°C and reconstitute in degassed buffer immediately before use.

Poor solubility usually indicates lyophilization technique or counterion selection, not purity. Peptides synthesized as trifluoroacetate (TFA) salts dissolve faster than acetate salts but are more hygroscopic and harder to dose accurately. If a peptide won't dissolve in bacteriostatic water at the expected concentration, try adjusting pH slightly with dilute acetic acid (lower pH for basic peptides) or ammonium hydroxide (raise pH for acidic peptides). If the peptide still clumps, aggregation may have occurred during storage due to temperature excursions above 8°C—aggregated peptides are functionally inactive even if HPLC purity was correct at synthesis. Request a replacement and verify cold chain integrity during shipping.

Normalize all peptide concentrations to the batch with the lowest purity to maintain internal consistency. If Batch A is 98.2% pure and Batch B is 96.8% pure, calculate the ratio (96.8 / 98.2 = 0.986) and multiply all concentrations prepared from Batch A by 0.986 before analyzing dose-response data. This correction assumes the impurities are biologically inactive. A reasonable assumption for deletion peptides in most cases but not for peptides where truncated sequences retain partial activity. For studies spanning multiple years where batch-to-batch variability could introduce artifacts, purchase a single large batch at the highest available purity and aliquot it for long-term storage at −80°C to eliminate purity drift as a variable. At Real Peptides, we've seen multi-year receptor pharmacology studies succeed or fail based entirely on whether the lab used a single batch or mixed batches without purity correction.

Walk away or request it before using the peptide. HPLC without MS is insufficient for sequence confirmation. You have no way to know if the primary peak is the correct peptide or a closely related compound with similar hydrophobicity. Some suppliers provide HPLC-only COAs for cost reasons, but this is a red flag for research applications. Real Peptides includes both HPLC and MS verification on every COA because sequence accuracy is non-negotiable for reproducible experiments.

You're looking at oxidation, most likely of methionine or cysteine residues. Add 16 Da per oxidized residue. This is common if the peptide wasn't stored under nitrogen or argon during lyophilization, or if it was exposed to air during reconstitution. Oxidized peptides lose biological activity. Methionine oxidation can reduce receptor binding affinity by 50–90% depending on the residue's position in the sequence. If oxidation exceeds 5% of total peptide mass (check the HPLC for secondary peaks at slightly later retention times), request a replacement batch or use a reducing agent during reconstitution to reverse some oxidation.

Temperature excursions during shipping can denature lyophilized peptides, especially those with disulfide bonds or oxidation-prone residues. If the vial wasn't shipped on dry ice or with cold packs and the shipping time exceeded 48 hours, the peptide may have partially degraded. Run your own HPLC or request the supplier provide post-shipping stability data. Some peptides tolerate brief temperature excursions (24–48 hours at 25°C), but others. Particularly those with multiple cysteine residues or unprotected methionine. Show measurable purity loss after just 72 hours above 8°C.